Alto Neuroscience, Inc. (ANRO) - Net Assets
Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has net assets worth $151.14 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($184.69 Million) and total liabilities ($33.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Alto Neuroscience, Inc. cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $151.14 Million |
| % of Total Assets | 81.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Alto Neuroscience, Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Alto Neuroscience, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Alto Neuroscience, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual net assets of Alto Neuroscience, Inc. from 2021 to 2025. For live valuation and market cap data, see Alto Neuroscience, Inc. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $151.14 Million | -0.21% |
| 2024-09-30 | $151.46 Million | +311.32% |
| 2023-09-30 | $-71.67 Million | -86.62% |
| 2022-09-30 | $-38.41 Million | -207.79% |
| 2021-09-30 | $-12.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alto Neuroscience, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18868400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $22.00K | 0.01% |
| Other Components | $352.75 Million | 233.39% |
| Total Equity | $151.14 Million | 100.00% |
Alto Neuroscience, Inc. Competitors by Market Cap
The table below lists competitors of Alto Neuroscience, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acast AB
ST:ACAST
|
$716.72 Million |
|
SLR Investment Corp
NASDAQ:SLRC
|
$716.85 Million |
|
Vgi Partners Global Investments Ltd
AU:VG1
|
$716.93 Million |
|
Aba Chemicals Corp
SHE:300261
|
$717.50 Million |
|
Media and Games Invest PLC
XETRA:M8G
|
$716.45 Million |
|
NTG Nordic Transport Group A/S
CO:NTG
|
$716.19 Million |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
$715.89 Million |
|
Sporton International
TWO:6146
|
$715.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alto Neuroscience, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 151,460,000 to 151,142,000, a change of -318,000 (-0.2%).
- Net loss of 63,238,000 reduced equity.
- Share repurchases of 167,000 reduced equity.
- New share issuances of 50,000,000 increased equity.
- Other comprehensive income increased equity by 123,000.
- Other factors increased equity by 12,964,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.24 Million | -41.84% |
| Share Repurchases | $167.00K | -0.11% |
| Share Issuances | $50.00 Million | +33.08% |
| Other Comprehensive Income | $123.00K | +0.08% |
| Other Changes | $12.96 Million | +8.58% |
| Total Change | $- | -0.21% |
Book Value vs Market Value Analysis
This analysis compares Alto Neuroscience, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $-0.49 | $20.44 | x |
| 2022-09-30 | $-1.50 | $20.44 | x |
| 2023-09-30 | $-2.67 | $20.44 | x |
| 2024-09-30 | $6.16 | $20.44 | x |
| 2025-09-30 | $5.24 | $20.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alto Neuroscience, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-41.84%) is below the historical average (-16.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -4374.76% | 0.01x | 0.00x | $-7.94 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.87 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.14 Million |
| 2024 | -40.56% | 0.00% | 0.00x | 1.17x | $-76.58 Million |
| 2025 | -41.84% | 0.00% | 0.00x | 1.22x | $-78.35 Million |
Industry Comparison
This section compares Alto Neuroscience, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | $151.14 Million | 0.00% | 0.22x | $716.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more